Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Selecting patients for therapy with a her inhibitor

An inhibitor, patient technology, applied in the direction of chemical instruments and methods, biochemical equipment and methods, and microbial assays/examinations, which can solve problems such as less favorable results

Inactive Publication Date: 2008-01-30
GENENTECH INC
View PDF114 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Less favorable outcomes for those with platinum-resistant disease

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Selecting patients for therapy with a her inhibitor
  • Selecting patients for therapy with a her inhibitor
  • Selecting patients for therapy with a her inhibitor

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0361] Example 1: Gene Expression Profiles Associated with HER2 Phosphorylation

[0362] Fresh ovarian tumor specimens from ovarian cancer patients treated with Pertuzumab were gene expression profiled for a small set of selected genes using AFFYMETRIX(R) microarray analysis. AFFYMETRIX(R) microarray analysis was performed according to the manufacturer's instructions.

[0363] Microarray expression data were analyzed to identify genotypes that would correlate with HER2 phosphorylation status. Notably, a pattern emerged in which tumors with relatively high levels of expression of EGFR, HER2, HER3, and the HER ligand betacelullin were also positive for HER2 phosphorylation. Figure 10 shows an unsupervised clustering of tumors with the above genes, resulting in clustering of 6 out of 6 phosphorylation positive tumors. Figure 11 shows that the phosphorylation status of ovarian tumors can be predicted by using an algorithm in which samples with betacellulin and HER2 expression at...

Embodiment 2

[0365] Example 2: Comparison of Microarray Analysis and qRT-PCR for Measuring Gene Expression

[0366] In this example, a second method for quantifying gene expression, quantitative real-time polymerase chain reaction (qRT-PCR), was used to validate and compare microarray data. qRT-PCT would be the preferred method for measuring gene expression in typical patient samples that can be obtained from a clinical setting. Diagnostic technology platforms for this approach have long been established.

[0367] qRT-PCR was performed as described in Cronin et al., Am. J. Pathol. 164(1):35-42 (2004) and Ma et al., Cancer Cell 5:607-616 (2004). RNA was extracted from frozen ovarian tumors using commercial reagents from Qiagen (Valencia, California). for TAQMAN TM Primers and probes for qRT-PCR analysis were designed to generate amplicons of approximately 100 bases or less in length. Use TAQMAN TM The facility (Applied BioSystems) quantified transcripts by qRT-PCR, normalizing the expr...

Embodiment 3

[0373] Example 3: Therapy for Patients with HER2 Phosphorylation-Associated Gene Expression Profiles

[0374] Examples 1 and 2 above demonstrate that gene expression profiling can be used as a surrogate for HER2 phosphorylation. In this example, patients whose tumors have a specific gene expression profile associated with HER2 phosphorylation are treated with the HER inhibitor Pertuzumab.

[0375] qRT-PCR was performed as described in Cronin et al., Am. J. Pathol. 164(1):35-42 (2004) and Ma et al., Cancer Cell 5:607-616 (2004). RNA was extracted from frozen ovarian tumors using commercial reagents from Qiagen (Valencia, California). for TAQMAN TM Primers and probes for qRT-PCR analysis were designed to generate amplicons of approximately 100 bases or less in length. Use TAQMAN TM The facility (Applied BioSystems) quantified transcripts by qRT-PCR, normalizing expression levels of test genes to reference genes.

[0376] An algorithm has been developed based on the gene exp...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Methods are described for selecting patients for therapy with HER inhibitors, such as Pertuzumab, based on gene expression analysis. Also described are methods of assessing HER phosphorylation or activation in biological samples by gene expression analysis.

Description

field of invention [0001] The present invention concerns methods for selecting patients for therapy with HER inhibitors, such as Pertuzumab, based on gene expression analysis. The present invention also contemplates methods of assessing HER phosphorylation or activation in biological samples by gene expression analysis. Background of the invention [0002] HER2 receptor and antibodies against it [0003] The HER family of receptor tyrosine kinases are important mediators of cell growth, differentiation and survival. This receptor family includes four distinct members, including epidermal growth factor receptor (EGFR, ErbB1 or HER1), HER2 (ErbB2 or p185 neu ), HER3 (ErbB3) and HER4 (ErbB4 or tyro2). [0004] EGFR, encoded by the erbB1 gene, has been causally linked to human malignancies. Specifically, elevated EGFR expression was observed in breast, bladder, lung, head, neck, and gastric cancers, as well as glioblastoma. Increased expression of the EGFR receptor is often...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12Q1/68
CPCG01N33/566G01N2333/91215C07K16/32C12Q2600/158C12Q1/6886G01N2333/485C12Q2600/106G01N33/5748C07K2317/24A61P35/00A61P35/04A61P43/00G01N33/57449
Inventor 卢卡斯·C·阿姆勒托马斯·E·贾纽埃里奥
Owner GENENTECH INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com